한글목차

ARCALYST의 성장을 이끄는 주요 요인들

1. 시장 점유율 확대 및 신규 환자 수 증가

• ARCALYST는 희귀 자가 염증성 질환 영역, 특히 재발성 심막염에서 우선적으로 선택되는 표적 치료제로서 시장 점유율을 지속적으로 확대하고 있습니다.
• 신규 환자 수가 크게 증가한 것은 순환기내과 및 류마티스내과에서의 채용 확대와 IL-1 매개 염증성 질환에 대한 인식이 높아진 것이 주요 원인으로 분석됩니다.
• Kiniksa Pharmaceuticals의 집중적인 상업적 전략, 전문의와의 협력, 환자 접근 프로그램 등을 통해 주요 시장에서의 보급이 가속화되고 있습니다.

2. 주요 적응증 확대

• 재발성 심막염: ARCALYST는 재발성 심막염의 치료 및 예방에 대한 승인을 받았으며, 임상 데이터에 따르면 증상이 빠르게 조절되고 재발률이 감소하는 것으로 나타났습니다.
• 크리오필린 관련 주기적 증후군(CAPS) : FCAS와 맥클웰 증후군을 포함한 희귀 자가 염증성 질환에 지속적으로 사용되고 있습니다.
• IL-1 관련 질환 확대: 실제 임상에서의 사용 실적과 파이프라인 탐색을 통해 추가적인 염증성 질환 및 심혈관계 질환에 대한 적용 확대 가능성을 보여주고 있습니다.
• 장기적인 질병 관리: 스테로이드 사용량을 줄이는 질병 조절 요법으로 채택이 증가하고 있습니다.

3. 지역적 확장

• ARCALYST는 미국 및 일부 국제 시장에서 시판되고 있습니다.
• 유럽 및 기타 지역의 규제 당국에 신청하고 상환 제도를 마련하는 등 보다 광범위한 접근성 지원을 위한 확대 노력이 진행 중입니다.
• Kiniksa는 전문 유통망 강화, 심장학 분야와의 제휴, 환자 지원 인프라 확충을 통해 전 세계 보급을 추진하고 있습니다.

4. 신규 적응증 승인

• ARCALYST는 미국 FDA로부터 재발성 심막염 적응증을 승인받아 초희귀 자가 염증성 질환을 넘어 상업적 잠재력을 크게 확대했습니다.
• 현재 진행 중인 임상 개발을 통해 다른 IL-1 관련 염증성 질환에 대한 적응증 확대가 기대됩니다.

5. 재발성 심막염의 견고한 판매 실적

• 재발성 심막염은 진단율과 전문의 의뢰가 증가함에 따라 여전히 주요 촉진요인으로 작용하고 있습니다.
• 당사의 최신 정보에서는 확실한 효능, 빠른 발현, 실제 임상 결과를 바탕으로 한 처방량의 견고한 증가를 강조하고 있습니다.
• ARCALYST는 코르티코스테로이드 치료가 효과를 나타내지 않는 경우 1차 선택 생물제제로서의 입지를 다져가고 있습니다.

6. 경쟁 우위 및 시장 동향

• 표적화된 IL-1α/IL-1베타 억제는 심낭염 및 CAPS에서 염증의 근본적인 메커니즘을 해결합니다.
• 주 1회 피하 투여는 매일 경구 투여나 빈번한 생물제제 투여에 비해 편리함을 제공합니다.
• 정밀 면역 분야, 스테로이드 절약 전략, 심장질환 분야에서의 생물제제 도입 확대 등 다양한 동향이 ARCALYST의 입지를 강화하고 있습니다.
• 리얼월드 증거에 대한 의존도가 높아짐에 따라 지불자와 처방자의 신뢰성이 강화되고 있습니다.

이 보고서는 미국, EU4(독일, 프랑스, 이탈리아, 스페인, 영국), 미국, EU7(독일, 프랑스, 이탈리아, 스페인), 영국 등 주요 7개국에서 ARCALYST의 승인된 적응증과 유육종증, 두드러기, 전신피부경화증, 선천성유전질환, 심막염, 유육종증 등 잠재적 적응증에 대한 종합적인 인사이트을 제공합니다. 2020-2034년까지 케케묵은 주요 7개국에서 ARCALYST의 승인된 적응증 및 잠재적 적응증에 대한 사용 현황, 진입 전망, 성과에 대한 상세한 전망과 함께 승인된 적응증 및 잠재적 적응증에 대한 ARCALYST의 상세한 설명을 제공합니다. 또한 이 약물의 매출 예측, 작용기전(MoA), 용량 및 투여방법, 규제 마일스톤을 포함한 연구개발 및 기타 활동에 대한 정보를 제공합니다. 또한 ARCALYST의 과거 및 현재 실적, 미래 시장 평가, SWOT 분석, 애널리스트의 견해, 경쟁사 개요, 각 적응증에 대한 다른 신흥 치료제의 개요, 매출 예측 분석, 시장 견인 요인 등을 정리했습니다.

목차

제1장 리포트 개요

제2장 ARCALYST 개요 : 크리오피린 관련 주기성 증후군, 선천성 유전성 질환, 심낭염 등의 승인 적응증·사코이도시스, 두드러기, 전신성 경피증 등의 잠재 적응증

제3장 ARCALYST : 경쟁 구도(출시 치료제)

제4장 ARCALYST : 경쟁 구도(개발 후기 치료제)

제5장 ARCALYST : 시장 평가

제6장 ARCALYST : SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving ARCALYST Growth

1. Market Share Gains and New Patient Starts

• ARCALYST continues to capture market share in the rare autoinflammatory disease segment, particularly in recurrent pericarditis, where it has become a preferred targeted therapy.
• A strong rise in new patient starts is being driven by cardiology and rheumatology adoption, as well as increasing awareness of IL-1-mediated inflammatory conditions.
• Kiniksa Pharmaceuticals' focused commercial execution, specialist engagement, and patient access programs are accelerating uptake across major markets.

2. Expansion Across Key Indications

• Recurrent Pericarditis: ARCALYST is approved for the treatment and prevention of recurrent pericarditis, with clinical data showing rapid symptom control and reduced recurrence rates.
• Cryopyrin-Associated Periodic Syndromes (CAPS): Continued use in rare autoinflammatory disorders, including FCAS and Muckle-Wells syndrome.
• Broader IL-1-Mediated Diseases: Real-world use and pipeline exploration support potential expansion into additional inflammatory and cardiovascular conditions.
• Long-Term Disease Control: Increasing adoption as a steroid-sparing, disease-modifying therapy.

3. Geographic Expansion

• ARCALYST is commercially available in the United States and select international markets.
• Expansion efforts are underway to support broader access in Europe and other regions through regulatory and reimbursement pathways.
• Kiniksa is strengthening specialty distribution, cardiology partnerships, and patient support infrastructure to drive global uptake.

4. New Indication Approvals

• ARCALYST received U.S. FDA approval for recurrent pericarditis, significantly expanding its commercial potential beyond ultra-rare autoinflammatory diseases.
• Ongoing clinical development may support label expansions into other IL-1-driven inflammatory conditions.

5. Strong Recurrent Pericarditis Volume Momentum

• Recurrent pericarditis remains the key growth driver, with increasing diagnosis rates and specialist referrals.
• Company updates highlight robust prescription growth, supported by strong efficacy, rapid onset, and real-world outcomes.
• ARCALYST is increasingly positioned as first-line biologic therapy after corticosteroid failure.

6. Competitive Differentiation and Market Trends

• Targeted IL-1a/IL-1B inhibition addresses the root inflammatory mechanism in pericarditis and CAPS.
• Weekly subcutaneous dosing offers convenience compared with daily oral or frequent biologic regimens.
• Broader trends toward precision immunology, steroid-sparing strategies, and biologic adoption in cardiology support ARCALYST's positioning.
• Growing reliance on real-world evidence (RWE) is strengthening payer and prescriber confidence.

ARCALYST Recent Developments

Kiniksa Pharmaceuticals has recently reported strong year-over-year revenue growth for ARCALYST, driven by expanding use in recurrent pericarditis. The company has announced continued label awareness initiatives, expanded cardiology engagement, and favorable long-term real-world data supporting durable remission and steroid-sparing benefits. These developments reinforce ARCALYST's position as a first-in-class IL-1 inhibitor for recurrent pericarditis and a cornerstone of Kiniksa's commercial portfolio.

"ARCALYST Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ARCALYST for approved indication like Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma in the 7MM. A detailed picture of ARCALYST's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ARCALYST for approved and potential indications. The ARCALYST market report provides insights about ARCALYST's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ARCALYST performance, future market assessments inclusive of the ARCALYST market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ARCALYST sales forecasts, along with factors driving its market.

ARCALYST Drug Summary

ARCALYST (Rilonacept) is a dimeric fusion protein acting as a soluble decoy receptor that selectively binds interleukin-1 alpha (IL-1a) and interleukin-1 beta (IL-1B) with high affinity, preventing their interaction with cell surface receptors and thereby inhibiting IL-1 signaling to reduce inflammation driven by NLRP3 inflammasome overactivation in cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) in adults and children 12 years and older, as well as recurrent pericarditis. Administered subcutaneously as a 320 mg loading dose followed by 160 mg weekly via pre-filled syringes (self-injectable after training), it rapidly normalizes elevated C-reactive protein (CRP) and serum amyloid A (SAA) levels, alleviating symptoms like rash, fever, arthralgia, and fatigue in CAPS while reducing pericarditis recurrence risk, with monitoring required for infections, malignancies, and injection-site reactions due to immunosuppression. The report provides ARCALYST's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ARCALYST Market Report

The report provides insights into:

• A comprehensive product overview including the ARCALYST MoA, description, dosage and administration, research and development activities in approved indications like Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma.
• Elaborated details on ARCALYST regulatory milestones and other development activities have been provided in ARCALYST market report.
• The report also highlights ARCALYST's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ARCALYST market report also covers the patents information, generic entry and impact on cost cut.
• The ARCALYST market report contains current and forecasted ARCALYST sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ARCALYST market report also features the SWOT analysis with analyst views for ARCALYST in approved and potential indications.

Methodology:

The ARCALYST market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARCALYST Analytical Perspective by DelveInsight

• In-depth ARCALYST Market Assessment

This ARCALYST sales market forecast report provides a detailed market assessment of ARCALYST for approved indication like Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ARCALYST sales data uptil 2034.

• ARCALYST Clinical Assessment

The ARCALYST market report provides the clinical trials information of ARCALYST for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ARCALYST Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ARCALYST Market Potential & Revenue Forecast

• Projected market size for the ARCALYST and its key indications
• Estimated ARCALYST sales potential (ARCALYST peak sales forecasts)
• ARCALYST Pricing strategies and reimbursement landscape

ARCALYST Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ARCALYST Market positioning compared to existing treatments
• ARCALYST Strengths & weaknesses relative to competitors

ARCALYST Regulatory & Commercial Milestones

• ARCALYST Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ARCALYST Clinical Differentiation

• ARCALYST Efficacy & safety advantages over existing drugs
• ARCALYST Unique selling points

ARCALYST Market Report Highlights

• In the coming years, the ARCALYST market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ARCALYST companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARCALYST's dominance.
• Other emerging products for Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma are expected to give tough market competition to ARCALYST and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARCALYST in approved and potential indications.
• Analyse ARCALYST cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ARCALYST sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ARCALYST in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ARCALYST? How strong is ARCALYST's clinical and commercial performance?
• What is ARCALYST's clinical trial status in each individual indications such as Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARCALYST Manufacturers?
• What are the key designations that have been granted to ARCALYST for approved and potential indications? How are they going to impact ARCALYST's penetration in various geographies?
• What is the current and forecasted ARCALYST market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ARCALYST in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARCALYST for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ARCALYST? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. ARCALYST Overview in approved indications like Cryopyrin-associated periodic syndromes, Inborn genetic disorders and Pericarditis; as well as potential indications like Sarcoidosis, Urticaria and Systemic scleroderma

• 2.1. Product Detail
• 2.2. ARCALYST Clinical Development
  • 2.2.1. ARCALYST Clinical studies
  • 2.2.2. ARCALYST Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. ARCALYST Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging ARCALYST Therapies)

5. ARCALYST Market Assessment

• 5.1. ARCALYST Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. ARCALYST Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. ARCALYST Market Size in the United States for approved and potential indications
  • 5.3.2. ARCALYST Market Size in Germany for approved and potential indications
  • 5.3.3. ARCALYST Market Size in France for approved and potential indications
  • 5.3.4. ARCALYST Market Size in Italy for approved and potential indications
  • 5.3.5. ARCALYST Market Size in Spain for approved and potential indications
  • 5.3.6. ARCALYST Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. ARCALYST Market Size in Japan for approved and potential indications

6. ARCALYST SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options